CORAL GABLES, FL / ACCESSWIRE / November 2, 2018 / Over the last few days, prices of the iShares Nasdaq Biotech ETF (IBB) as well as the SPDR Healthcare ETF (XLV) have recovered from previous lows this week. The healthcare sector is often regarded as a hedge from regular market forces. Recent volatility has brought this particular topic to light ahead of US midterm elections. Care in the form of providers, equipment, medicine, technology and services is linked to increasing demand as the aging population grows. Today we're taking a closer look at Premier Health Group, Inc. (PHGRF)(PHGI.CN), Titan Pharmaceuticals (TTNP) and Pacific Biosciences of CA Inc. (PACB)
Premier Health Group, Inc. (PHGRF)(PHGI.CN) saw its shares trade higher on Thursday. Market activity in the United States appears to have picked up after the company's most recent announcement. Shares of Premier Health Group, Inc. (PHGRF)(PHGI.CN) have begun to trade on the OTC Markets Group Inc.'s OTCQB Venture Market in the United States, under the symbol PHGRF in late October, and are now Depository Trust Company eligible, effective Oct. 22, 2018.
Premier Health Group, Inc. (PHGRF)(PHGI.CN) previously acquired HealthVue Medical Clinics in August. With this acquisition, Premier entered the primary care clinic and healthcare technology business. HealthVue is a group of four Greater Vancouver-based fully integrated, paperless and electronic-medical-record-based medical clinics with a 10-year history, 22 healthcare professionals and over 100,000 active patients. The clinics have seen revenue growth in excess of 25 percent year over year for the past three years and thus far accounted for over 36,000 patient visits in 2018. HealthVue will open its fifth clinic in Q4 2018.
In the U.S. market, alone, the Telehealth industry is on fire right now, predicted to reach a $2.8 billion valuation by 2025, with the heat only intensifying with time. According to Reuters, the deployment of telemedicine has significantly altered the healthcare paradigm, due to the many technological advancements in the field of medical devices and services.
Titan Pharmaceuticals (TTNP) has seen higher trading volume over the last week. ProNeura™, Titan's innovative drug delivery platform, is advancing the treatment of select chronic diseases by delivering low-dose, non-fluctuating medication levels for up to one year following a single procedure.
Titan Pharmaceuticals develops proprietary therapeutics for the treatment of select chronic diseases. The company's lead product is Probuphine, a six-month buprenorphine implant for the maintenance treatment of opioid addiction. The U.S. Food and Drug Administration approved Probuphine on May 26, 2016. Probuphine is the first marketed product to provide maintenance treatment of opioid addiction continuously for six months, according to the company.
Last month, Knight Therapeutics Inc. (TSXGUD) announced the commercial availability of PROBUPHINE™ (buprenorphine hydrochloride subdermal implant), for the management of opioid dependence in patients clinically stabilized on no more than 8 mg of sublingual buprenorphine in combination with counseling and psychosocial support1. Knight has the exclusive right to distribute PROBUPHINE in Canada under a license agreement with Titan Pharmaceuticals, Inc.
Shares of Titan reached early highs of $0.3385 on Friday morning
Shares of Pacific Biosciences of California (PACB) were rallying to a two-year high in pre-market trading on Friday. The company is a developer of systems for gene sequencing and announced an agreement to be bought by rival Illumina, Inc. (ILMN) in a deal valued at about $1.2 billion, or $8 per share in cash. The per share value represented a 77% premium over the $4.51 at which Pacific Biosciences shares closed Thursday.
Illumina is the maker of DNA sequencing machines and said the acquisition complements sequencing solutions with accurate long-read sequencing capabilities to answer complex genomic questions.
"Combining the two technologies positions us to reach more applications, accelerate the pace of genomic discovery and bolster our innovation engine which has been a hallmark of Illumina since our inception," Illumina Chief Executive Francis deSouza said in a prepared statement.
What Is Stock Price (StockPrice.com)?
Stock Price is defined as the price of a single share of a number of saleable stocks of a public company. A stock price is the highest amount an investor or trader is willing to pay for the stock, or the lowest amount that it can be bought for.
StockPrice.com was created for everyone that wants the latest stock quotes, stock charts, company news, and the best financial content.
At Stock Price (StockPrice.com), you get free stock quotes, up-to-date news, international market data, social interaction and the best financial content that will help you manage your financial life.
Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. JSG Communications, LLC which owns www.StockPrice.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release.
JSG Communications, LLC, which owns www.StockPrice.com, may from time to time have a position in the securities mentioned herein and may increase or decrease such positions without notice. For making specific investment decisions, readers should seek their own advice. JSG Communications, LLC, which owns www.StockPrice.com, may be compensated for its services in the form of cash-based compensation or equity securities in the companies it writes about, or a combination of the two. Pursuant to an agreement between MIDAM VENTURES, LLC an affiliate of JSG COMMUNICATIONS LLC and Premier Health Group Inc. we were hired for a period from 10/1/2018 – 4/1/2018 to publicly disseminate information about Premier Health Group Inc. including on the Website and other media including Facebook and Twitter. We were paid $100,000 (CASH) for & were paid "500,000" shares of restricted common shares. We own zero shares of Premier Health Group Inc., which we purchased in the open market. Once the (6)Six month restriction is complete on 4/1/2019 we plan to sell the "500,000" shares of Premier Health Group Inc. that we hold currently in restricted form during the time the Website and/or Facebook and Twitter Information recommends that investors or visitors to the website purchase without further notice to you. We may buy or sell additional shares of Premier Health Group Inc. in the open market at any time, including before, during or after the Website and Information, provide public dissemination of favorable Information. Please click here for full disclaimer.